KRAS and neoplasm: A study of 419 CRC patients with unresectable liver metastases showed that the KRAS A146 mutations had a high tumor burden (TMB) and a worse OS compared with the G12 subtypes (median OS 10.7 months vs. 26.4 months; p = 0.003) [45].